Evommune, Inc. - 8-K Filing
Evommune reports Q3 2026 net loss of $30.9 million and announces $30 million private placement alongside EVO570 in-licensing. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)